![]() |
|
|
Vol. 59, Issue 6, 1388-1394, June 2001
Department of Biochemistry and Molecular Biology, University of
Debrecen, Medical and Health Science Center, Faculty of Medicine,
Debrecen, Hungary (I.P.U., L.F.); and Department of Integrative Biology
and Pharmacology, University of Texas at Houston Medical School,
Houston, Texas (I.P.U., P.J.A.D.)
Chemotherapeutic drugs are known to eliminate cancer cells by inducing
apoptosis. Tissue transglutaminase (tTG), a frequent player in
apoptotic processes, is markedly induced in drug-resistant cancer
cells. To better understand the action of apoptosis-inducing drugs, our
study elucidates changes in the expression of tTG in the early phase of
cell death, before the downstream events of apoptosis. We demonstrate
that HepG2 cells uniformly induce both tTG mRNA and enzyme activity
upon treatment with cisplatin, doxorubicin, and bleomycin,
chemotherapeutic agents with different modes of action. The expression
of fas ligand, caspase3 and bax
changes differentially or remain
unaffected. tTG expression did not change significantly after
administration of either the peroxisome proliferator activated
receptor-
agonist WY14643 or the retinoid X receptor-specific analog
LG 100268. However, both compounds blocked drug-induced tTG induction
without affecting the extent of cell death. The pleiotropic cytokine
interleukin-6 effectively rescued hepatoma cells from apoptosis while
tTG induction still took place, along with the induction of
antiapoptotic transcripts bcl-xL, gp130, and
her2/neu. These results suggest that the induction of tTG, although present in drug-induced apoptosis, is pharmacologically dissociable from the early, initiating events of apoptosis. Blocking the induction of tTG during drug-induced cell death may alleviate limiting side effects of anticancer agents, including fibrosis and neuropathies.
This article has been cited by other articles:
![]() |
F. Al-Ejeh, J. M. Darby, and M. P. Brown The La Autoantigen Is a Malignancy-Associated Cell Death Target That Is Induced by DNA-Damaging Drugs Clin. Cancer Res., September 15, 2007; 13(18): 5509s - 5518s. [Abstract] [Full Text] [PDF] |
||||